Heilig Philipp, Sandner Phoebe, Jordan Martin Cornelius, Jakubietz Rafael Gregor, Meffert Rainer Heribert, Gbureck Uwe, Hoelscher-Doht Stefanie
Department of Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital of Würzburg, Oberdürrbacherstraße 6, 97080 Würzburg, Germany.
Department for Functional Materials in Medicine and Dentistry, University of Würzburg, Pleicherwall 2, 97070 Würzburg, Germany.
Materials (Basel). 2021 Apr 12;14(8):1925. doi: 10.3390/ma14081925.
Clinically used mineral bone cements lack high strength values, absorbability and drillability. Therefore, magnesium phosphate cements have recently received increasing attention as they unify a high mechanical performance with presumed degradation in vivo. To obtain a drillable cement formulation, farringtonite (Mg(PO)) and magnesium oxide (MgO) were modified with the setting retardant phytic acid (CHOP). In a pre-testing series, 13 different compositions of magnesium phosphate cements were analyzed concentrating on the clinical demands for application. Of these 13 composites, two cement formulations with different phytic acid content (22.5 wt% and 25 wt%) were identified to meet clinical demands. Both formulations were evaluated in terms of setting time, injectability, compressive strength, screw pullout tests and biomechanical tests in a clinically relevant fracture model. The cements were used as bone filler of a metaphyseal bone defect alone, and in combination with screws drilled through the cement. Both formulations achieved a setting time of 5 min 30 s and an injectability of 100%. Compressive strength was shown to be ~12-13 MPa and the overall displacement of the reduced fracture was <2 mm with and without screws. Maximum load until reduced fracture failure was ~2600 N for the cements only and ~3800 N for the combination with screws. Two new compositions of magnesium phosphate cements revealed high strength in clinically relevant biomechanical test set-ups and add clinically desired characteristics to its strength such as injectability and drillability.
临床使用的矿物骨水泥缺乏高强度值、可吸收性和可钻性。因此，磷酸镁水泥最近受到越来越多的关注，因为它们兼具高机械性能和体内假定的降解性。为了获得可钻性水泥配方，用缓凝剂植酸（C₆H₁₈O₂₄P₆）对镁橄榄石（Mg₂SiO₄）和氧化镁（MgO）进行了改性。在一个预测试系列中，分析了13种不同成分的磷酸镁水泥，重点关注临床应用需求。在这13种复合材料中，确定了两种不同植酸含量（22.5 wt%和25 wt%）的水泥配方符合临床需求。在临床相关骨折模型中，对这两种配方的凝固时间、可注射性、抗压强度、螺钉拔出试验和生物力学试验进行了评估。这些水泥单独用作干骺端骨缺损的骨填充材料，并与穿过水泥钻出的螺钉联合使用。两种配方的凝固时间均为5分30秒，可注射性均为100%。抗压强度显示约为12 - 13 MPa，无论有无螺钉，骨折复位后的总位移均<2 mm。仅使用水泥时，骨折复位失败前的最大载荷约为2600 N，与螺钉联合使用时约为3800 N。两种新的磷酸镁水泥配方在临床相关生物力学试验设置中显示出高强度，并为其强度增添了临床所需的特性，如可注射性和可钻性。
